Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other important ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck expects 2% to 4% growth in Gardasil sales, with no further shipments of Gardasil to China at the low end and less than $1 billion in revenue from the country at the high end, the ...

to 4.6% in 2025 and 4.5% in 2026. A collapse in the Chinese housing market has undermined consumer confidence. Overall sales of Gardasil fell 17% to $1.55 billion in the final quarter of last year ...